摘要: Anti-IgE antibodies directed against the Fc epsilon RI-binding region on IgE inhibit binding of to receptors without inducing mediator release from sensitized cells. In mice these selectively reduce serum IgE, antigen induced skin reactions, cytokine production by lung Th2 cells, and pulmonary eosinophil infiltration. Clinical trials in humans reveal that such are well tolerated rhinitis symptoms early late phase bronchoconstriction responses. Thus interruption allergic cascade at antibody level with non-anaphylactogenic anti-IgE is effective represents an attractive intervention for treatment diseases.